SCHEMBL7215327

SCHEMBL7215327

NS(=O)(=O)c1ccc(-c2c(-c3ccc(F)cc3)nc3ncccn23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.49
AKT2 P31751 1/20 0.49
MAPK13 O15264 1/20 0.49
MAPK12 P53778 1/20 0.49
MAPK11 Q15759 1/20 0.49
MAPK14 Q16539 1/20 0.49
PTGS2 P35354 9/20 0.46
PTGS1 P23219 7/20 0.46
ROCK2 O75116 1/20 0.45
PIM1 P11309 1/20 0.45
GSK3B P49841 1/20 0.45
KLK7 P49862 1/20 0.44
GPBAR1 Q8TDU6 1/20 0.44
ALOX5 P09917 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7215540 0.90 AKT1 (0.60) AKT1AKT2PTGS2PTGS1ROCK2
SCHEMBL7217037 0.89 ROCK2 (0.49) AKT1AKT2MAPK13MAPK12MAPK11
SCHEMBL7220427 0.88 AKT1 (0.49) AKT1AKT2PTGS2PTGS1ROCK2
SCHEMBL5260680 0.88 AKT1 (0.49) AKT1AKT2PTGS2ROCK2PIM1
SCHEMBL7217077 0.88 PTGS2 (0.60) AKT1AKT2MAPK13MAPK12MAPK11
SCHEMBL5261262 0.88 PTGS2 (0.60) AKT1AKT2MAPK13MAPK12MAPK11
SCHEMBL7222717 0.85 KDM4E (0.59) AKT1AKT2PTGS2PTGS1ROCK2
SCHEMBL9298535 0.82 MAPK14 (0.66) AKT1AKT2MAPK13MAPK12MAPK11
SCHEMBL7215376 0.82 PTGS2 (0.53) PTGS2PTGS1KLK7KDM4EALDH1A1
SCHEMBL7220640 0.82 ROCK2 (0.49) AKT1AKT2PTGS2PTGS1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670365-B1 Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2003-12-30 US claimed
US-6670365-B1 Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2003-12-30 US disclosed
EP-1104762-B1 SUBSTITUTED IMIDAZO[1,2A]AZINES AS SELECTIVE INHIBITORS OF COX-2 S A L V A T LAB SA (ES) 2002-09-18 EP disclosed
EP-1104762-A1 SUBSTITUTED IMIDAZO 1,2A]AZINES AS SELECTIVE INHIBOTORS OF COX-2 LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2001-06-06 EP disclosed